<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">27919039</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>01</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>02</Month>
        <Day>21</Day>
      </DateRevised>
      <Article PubModel="Electronic-Print">
        <Journal>
          <ISSN IssnType="Electronic">1573-4935</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>34</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2014</Year>
              <Month>Apr</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>Bioscience reports</Title>
          <ISOAbbreviation>Biosci Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Perspectives of the AMP-activated kinase (AMPK) signalling pathway in thyroid cancer.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e00105</ELocationID>
        <Abstract>
          <AbstractText>Approximately 90% of non-medullary thyroid malignancies originate from the follicular cell and are classified as papillary or follicular (well-differentiated) thyroid carcinomas, showing an overall favourable prognosis. However, recurrence or persistence of the disease occurs in some cases associated with the presence of loco-regional or distant metastatic lesions that generally become resistant to radioiodine therapy, while glucose uptake and metabolism are increased. Recent advances in the field of tumor progression have shown that CTC (circulating tumour cells) are metabolic and genetically heterogeneous. There is now special interest in unravelling the mechanisms that allow the reminiscence of dormant tumour lesions that might be related to late disease progression and increased risk of recurrence. AMPK (AMP-activated protein kinase) is activated by the depletion in cellular energy levels and allows adaptive changes in cell metabolism that are fundamental for cell survival in a stressful environment; nevertheless, the activation of this kinase also decreases cell proliferation rate and induces tumour cell apoptosis. In the thyroid field, AMPK emerged as a novel important intracellular pathway, since it regulates both iodide and glucose uptakes in normal thyroid cells. Furthermore, it has recently been demonstrated that the AMPK pathway is highly activated in papillary thyroid carcinomas, although the clinical significance of these findings remains elusive. Herein we review the current knowledge about the role of AMPK activation in thyroid physiology and pathophysiology, with special focus on thyroid cancer.</AbstractText>
          <CopyrightInformation>© 2014 The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Andrade</LastName>
            <ForeName>Bruno Moulin</ForeName>
            <Initials>BM</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Fisiologia Endócrina, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>de Carvalho</LastName>
            <ForeName>Denise Pires</ForeName>
            <Initials>DP</Initials>
            <AffiliationInfo>
              <Affiliation>Laboratório de Fisiologia Endócrina, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil dencarv@biof.ufrj.br.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2014</Year>
          <Month>04</Month>
          <Day>01</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Biosci Rep</MedlineTA>
        <NlmUniqueID>8102797</NlmUniqueID>
        <ISSNLinking>0144-8463</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>EC 2.7.11.31</RegistryNumber>
          <NameOfSubstance UI="D055372">AMP-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D055372" MajorTopicYN="N">AMP-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002291" MajorTopicYN="N">Carcinoma, Papillary</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009360" MajorTopicYN="N">Neoplastic Cells, Circulating</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077273" MajorTopicYN="N">Thyroid Cancer, Papillary</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013964" MajorTopicYN="N">Thyroid Neoplasms</DescriptorName>
          <QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">AMPK</Keyword>
        <Keyword MajorTopicYN="Y">NIS</Keyword>
        <Keyword MajorTopicYN="Y">Warburg effect</Keyword>
        <Keyword MajorTopicYN="Y">mTOR</Keyword>
        <Keyword MajorTopicYN="Y">metformin</Keyword>
        <Keyword MajorTopicYN="Y">thyroid cancer</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2013</Year>
          <Month>12</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2014</Year>
          <Month>2</Month>
          <Day>17</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2014</Year>
          <Month>2</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>12</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2014</Year>
          <Month>4</Month>
          <Day>1</Day>
          <Hour>0</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">27919039</ArticleId>
        <ArticleId IdType="pmc">PMC3986867</ArticleId>
        <ArticleId IdType="doi">10.1042/BSR20130134</ArticleId>
        <ArticleId IdType="pii">BSR20130134</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tan G. H., Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann. Intern. Med. 1997;126:226–231. doi: 10.7326/0003-4819-126-3-199702010-00009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/0003-4819-126-3-199702010-00009</ArticleId>
            <ArticleId IdType="pubmed">9027275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morganti S., Ceda G. P., Saccani M., Milli B., Ugolotti D., Prampolini R., Maggio M., Valenti G., Ceresini G. Thyroid disease in the elderly: sex-related differences in clinical expression. J. Endocrinol. Invest. 2005;28:101–104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16760635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Momesso D. P., Vaisman F., Cordeiro de Noronha Pessoa C. H., Corbo R., Vaisman M. Small differentiated thyroid cancer: time to reconsider clinical management and treatment. Surg. Oncol. 2012;21:257–262. doi: 10.1016/j.suronc.2012.06.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.suronc.2012.06.002</ArticleId>
            <ArticleId IdType="pubmed">22770922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coelho S. M., Vaisman M., Carvalho D. P. Tumour re-differentiation effect of retinoic acid: a novel therapeutic approach for advanced thyroid cancer. Curr. Pharm. Des. 2005;11:2525–2531. doi: 10.2174/1381612054367490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/1381612054367490</ArticleId>
            <ArticleId IdType="pubmed">16026305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bhaijee F., Nikiforov Y. E. Molecular analysis of thyroid tumors. Endocr. Pathol. 2011;22:126–133. doi: 10.1007/s12022-011-9170-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-011-9170-y</ArticleId>
            <ArticleId IdType="pubmed">21739166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen A. Y., Jemal A., Ward E. M. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 2009;115:3801–3807. doi: 10.1002/cncr.24416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cncr.24416</ArticleId>
            <ArticleId IdType="pubmed">19598221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davies L., Welch H. G. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295:2164–2167. doi: 10.1001/jama.295.18.2164.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.295.18.2164</ArticleId>
            <ArticleId IdType="pubmed">16684987</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albores-Saavedra J., Henson D. E., Glazer E., Schwartz A. M. Changing patterns in the incidence and survival of thyroid cancer with follicular phenotype-papillary, follicular, and anaplastic: a morphological and epidemiological study. Endocr. Pathol. 2007;18:1–7. doi: 10.1007/s12022-007-0002-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12022-007-0002-z</ArticleId>
            <ArticleId IdType="pubmed">17652794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colonna M., Guizard A. V., Schvartz C., Velten M., Raverdy N., Molinie F., Delafosse P., Franc B., Grosclaude P. A time trend analysis of papillary and follicular cancers as a function of tumour size: a study of data from six cancer registries in France (1983–2000) Eur. J. Cancer. 2007;43:891–900. doi: 10.1016/j.ejca.2006.11.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2006.11.024</ArticleId>
            <ArticleId IdType="pubmed">17289376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burgess J. R., Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine needle aspirate cytology. Thyroid. 2006;16:47–53. doi: 10.1089/thy.2006.16.47.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2006.16.47</ArticleId>
            <ArticleId IdType="pubmed">16487013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Instituto Nacional de Cancer Jose de Alencar Gomes da Silva. Estimativa 2012: incidência de cancer no Brasil. INCA: Rio de Janeiro; 2011. p. 118.</Citation>
        </Reference>
        <Reference>
          <Citation>Jung C. K., Little M. P., Lubin J. H., Brenner A. V., Wells S. A., Jr, Sigurdson A. J., Nikiforov Y. E. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J. Clin. Endocrinol. Metab. 2014;99:E276–E285. doi: 10.1210/jc.2013-2503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2013-2503</ArticleId>
            <ArticleId IdType="pmc">PMC3913801</ArticleId>
            <ArticleId IdType="pubmed">24248188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vaisman F., Momesso D., Bulzico D. A., Pessoa C. H., Dias F., Corbo R., Vaisman M., Tuttle R. M. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin. Endocrinol. (Oxf.). 2012;77:132–138. doi: 10.1111/j.1365-2265.2012.04342.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1365-2265.2012.04342.x</ArticleId>
            <ArticleId IdType="pubmed">22248037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W., Larson S. M., Tuttle R. M., Kalaigian H., Kolbert K., Sonenberg M., Robbins R. J. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid. 2001;12:1169–1175. doi: 10.1089/10507250152741028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/10507250152741028</ArticleId>
            <ArticleId IdType="pubmed">12186505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Lellis A. R., Lloyd R. V., Heitz P. U., Eng C.  Thyroid and parathyroid tumors. In: De Lellis A. R., Williams E. D., editors. Pathology and Genetics of Tumors of Endocrine Organs. World Health Organization Classification of Tumors. 1st edn. Lyon: WHO, IARC; 2004. pp. 49–133.</Citation>
        </Reference>
        <Reference>
          <Citation>Bizhanova A., Chop P. The sodium-iodide symporter NIS and Pendrin in iodide homeostasis of the thyroid. Endocrinology. 2009;150:1084–1090. doi: 10.1210/en.2008-1437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/en.2008-1437</ArticleId>
            <ArticleId IdType="pmc">PMC2654752</ArticleId>
            <ArticleId IdType="pubmed">19196800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carvalho D. P., Ferreira A. C. The importance of sodium/iodide symporter (NIS) for thyroid cancer management. Arq. Bras. Endocrinol. Metabol. 2007;51:672–682. doi: 10.1590/S0004-27302007000500004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1590/S0004-27302007000500004</ArticleId>
            <ArticleId IdType="pubmed">17891230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrade B. M., Araujo R. L., Perry R. L., Souza E. C., Cazarin J. M., Carvalho D. P., Ceddia R. B. A novel role for AMP-kinase in the regulation of the Na+/I−-symporter and iodide uptake in the rat thyroid gland. Am. J. Physiol. Cell Physiol. 2011;300:C1291–C1297. doi: 10.1152/ajpcell.00136.2010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/ajpcell.00136.2010</ArticleId>
            <ArticleId IdType="pubmed">21389275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrade B. M., Cazarin J., Zancan P., Carvalho D. P. AMP-activated protein kinase upregulates glucose uptake in thyroid PCCL3 cells independent of thyrotropin. Thyroid. 2012;22:1063–1068. doi: 10.1089/thy.2012.0041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2012.0041</ArticleId>
            <ArticleId IdType="pubmed">22953992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rattan R., Giri S., Singh A. K., Singh I. 5–Aminoimidazole-4–carboxamide-1–beta-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J. Biol. Chem. 2005;280:39582–39593. doi: 10.1074/jbc.M507443200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M507443200</ArticleId>
            <ArticleId IdType="pubmed">16176927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vidal A. P., Andrade B. M., Vaisman F., Cazarin J., Pinto L. F., Breitenbach M. M., Corbo R., Caroli-Bottino A., Soares F., Vaisman M., Carvalho D. P. AMP-activated protein kinase signaling is upregulated in papillary thyroid cancer. Eur. J. Endocrinol. 2013;169:521–528. doi: 10.1530/EJE-13-0284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/EJE-13-0284</ArticleId>
            <ArticleId IdType="pubmed">23904275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo Z., Zang M., Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol. 2010;6:457–470. doi: 10.2217/fon.09.174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2217/fon.09.174</ArticleId>
            <ArticleId IdType="pmc">PMC2854547</ArticleId>
            <ArticleId IdType="pubmed">20222801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hardie D. G. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011;25:1895–1908. doi: 10.1101/gad.17420111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.17420111</ArticleId>
            <ArticleId IdType="pmc">PMC3185962</ArticleId>
            <ArticleId IdType="pubmed">21937710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hardie D. G., Alessi D. R. LKB1 and AMPK and the cancer-metabolism link–ten years after. BMC Biol. 2013;15:11–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3626889</ArticleId>
            <ArticleId IdType="pubmed">23587167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cairns R. A., Harris I. S., Mak T. W. Regulation of cancer cell metabolism. Nat. Rev. Cancer. 2011;11:85–95. doi: 10.1038/nrc2981.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2981</ArticleId>
            <ArticleId IdType="pubmed">21258394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shackelford D. B., Vasquez D. S., Corbeil J., Wu S., Leblanc M., Wu C. L., Vera D. R., Shaw R. J. mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc. Natl. Acad. Sci. U.S.A. 2009;106:11137–11142. doi: 10.1073/pnas.0900465106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0900465106</ArticleId>
            <ArticleId IdType="pmc">PMC2708689</ArticleId>
            <ArticleId IdType="pubmed">19541609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdulrahman R. M., Boon M. R., Sips H. C., Guigas B., Rensen P. C., Smit J. W., Hovens G. C. Impact of Metformin and compound C on NIS expression and iodine uptake in vitro and in vivo: a role for CRE in AMPK modulation of thyroid function. Thyroid. 2013;24:78–87. doi: 10.1089/thy.2013.0041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2013.0041</ArticleId>
            <ArticleId IdType="pubmed">23819433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones R. G., Plas D. R., Kubek S., Buzzai M., Mu J., Xu Y., Birnbaum M. J., Thompson C. B. AMP-activated protein kinase induces a p53- dependent metabolic checkpoint. Mol. Cell. 2005;18:283–293. doi: 10.1016/j.molcel.2005.03.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2005.03.027</ArticleId>
            <ArticleId IdType="pubmed">15866171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadad S. M., Baker L., Quinlan P. R., Robertson K. E., Bray S. E., Thomson G., Kellock D., Jordan L. B., Purdie C. A., Hardie D. G., et al.  Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer. 2009;9:307–311. doi: 10.1186/1471-2407-9-307.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-9-307</ArticleId>
            <ArticleId IdType="pmc">PMC2744705</ArticleId>
            <ArticleId IdType="pubmed">19723334</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbassov D. D., Ali S. M., Sabatini D. M. Growing roles for the mTOR pathway Curr. Opin. Cell. Biol. 2005;17:596–603. doi: 10.1016/j.ceb.2005.09.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ceb.2005.09.009</ArticleId>
            <ArticleId IdType="pubmed">16226444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buzzai M., Bauer D. E., Jones R. G., Deberardinis R. J., Hatzivassiliou G., Elstrom R. L., Thompson C. B. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene. 2005;24:4165–4173. doi: 10.1038/sj.onc.1208622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.onc.1208622</ArticleId>
            <ArticleId IdType="pubmed">15806154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jeon S. M., Hay N. The dark face of AMPK as an essential tumor promoter. Cell Logist. 2012;2:197–202. doi: 10.4161/cl.22651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cl.22651</ArticleId>
            <ArticleId IdType="pmc">PMC3607621</ArticleId>
            <ArticleId IdType="pubmed">23676995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee M., Hwang J. T., Yun H. Critical roles of AMP-activated protein kinase in the carcinogenic metal-induced expression of VEGF and HIF-1 proteins in DU145 prostate carcinoma. Biochem. Pharmacol. 2006;72:91–103. doi: 10.1016/j.bcp.2006.03.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bcp.2006.03.021</ArticleId>
            <ArticleId IdType="pubmed">16678800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koperek O., Akin E., Asari R., Niederle B., Neuhold N. Expression of hypoxia-inducible factor 1 alpha in papillary thyroid carcinoma is associated with desmoplastic stromal reaction and lymph node metastasis. Virchows Arch. 2013;463:795–802. doi: 10.1007/s00428-013-1484-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00428-013-1484-3</ArticleId>
            <ArticleId IdType="pubmed">24197448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mo J. H., Choi I. J., Jeong W. J., Jeon E. H., Ahn S. H. HIF-1α and HSP90: target molecules selected from a tumorigenic papillary thyroid carcinoma cell line. Cancer Sci. 2012;103:464–467. doi: 10.1111/j.1349-7006.2011.02181.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1349-7006.2011.02181.x</ArticleId>
            <ArticleId IdType="pmc">PMC7713618</ArticleId>
            <ArticleId IdType="pubmed">22151618</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu C. A., Chao Y., Shiah S. G., Lin W. W. Nutrient deprivation induces the Warburg effect through ROS/AMPK-dependent activation of pyruvate dehydrogenase kinase. Biochim. Biophys. Acta. 2013;1833:1147–1156. doi: 10.1016/j.bbamcr.2013.01.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.bbamcr.2013.01.025</ArticleId>
            <ArticleId IdType="pubmed">23376776</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phay J. E., Ringel M. D. Metastatic mechanisms in follicular cell-derived thyroid cancer. Endocr. Relat. Cancer. 2013;20:R307–R319. doi: 10.1530/ERC-13-0187.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/ERC-13-0187</ArticleId>
            <ArticleId IdType="pmc">PMC4196318</ArticleId>
            <ArticleId IdType="pubmed">24036131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rezzonico J., Rezzonico M., Pusiol E., Pitoia F., Niepomniszcze H. Introducing the thyroid gland as another victim of the insulin resistance syndrome. Thyroid. 2008;18:461–464. doi: 10.1089/thy.2007.0223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/thy.2007.0223</ArticleId>
            <ArticleId IdType="pubmed">18346005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rezzonico J. N., Rezzonico M., Pusiol E., Pitoia F., Niepomniszcze H. Increased prevalence of insulin resistance in patients with differentiated thyroid carcinoma. Metab. Syndr. Relat. Disord. 2009;7:375–380. doi: 10.1089/met.2008.0062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/met.2008.0062</ArticleId>
            <ArticleId IdType="pubmed">19320560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malek M., Aghili R., Emami Z., Khamseh M. E. Risk of cancer in diabetes: the effect of Metformin. ISRN Endocrinol. 2013;2013:ID636927. doi: 10.1155/2013/636927.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2013/636927</ArticleId>
            <ArticleId IdType="pmc">PMC3800579</ArticleId>
            <ArticleId IdType="pubmed">24224094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ben Sahra I., Le Marchand-Brustel Y., Tanti J. F., Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol. Cancer Ther. 2009;9:1092–1099. doi: 10.1158/1535-7163.MCT-09-1186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1535-7163.MCT-09-1186</ArticleId>
            <ArticleId IdType="pubmed">20442309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Mir M. Y., Nogueira V., Fontaine E., Avéret N., Rigoulet M., Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J. Biol. Chem. 2000;275:223–228. doi: 10.1074/jbc.275.1.223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.275.1.223</ArticleId>
            <ArticleId IdType="pubmed">10617608</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miskimins W. K., Ahn H. J., Kim J. Y., Ryu S., Jung Y. S., Choi J. Y. Synergistic anti-cancer effect of phenformin and oxamate. PLoS ONE. 2014;9:e85576. doi: 10.1371/journal.pone.0085576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0085576</ArticleId>
            <ArticleId IdType="pmc">PMC3897486</ArticleId>
            <ArticleId IdType="pubmed">24465604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fumarola C., Caffarra C., La Monica S., Galetti M., Alfieri R. R., Cavazzoni A., Galvani E., Generali D., Petronini P. G., Bonelli M. A. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling. Breast Cancer Res. Treat. 2013;141:67–78. doi: 10.1007/s10549-013-2668-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-013-2668-x</ArticleId>
            <ArticleId IdType="pubmed">23963659</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaw R. J. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol. (Oxf.) 2009;196:65–80. doi: 10.1111/j.1748-1716.2009.01972.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1748-1716.2009.01972.x</ArticleId>
            <ArticleId IdType="pmc">PMC2760308</ArticleId>
            <ArticleId IdType="pubmed">19245654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin-Castillo B., Vazquez-Martin A., Oliveras-Ferraros C., Menendez J. A. Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena. Cell Cycle. 2009;9:1057–1064. doi: 10.4161/cc.9.6.10994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/cc.9.6.10994</ArticleId>
            <ArticleId IdType="pubmed">20305377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi H. J., Kim T. Y., Chung N., Yim J. H., Kim W. G., Kim J. A., Kim W. B., Shong Y. K. The influence of the BRAF V600E mutation in thyroid cancer cell lines on the anticancer effects of 5-aminoimidazole-4-carboxamide-ribonucleoside. J. Endocrinol. 2011;211:79–85. doi: 10.1530/JOE-11-0260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/JOE-11-0260</ArticleId>
            <ArticleId IdType="pubmed">21795305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faustino A., Couto J. P., Pópulo H., Rocha A. S., Pardal F., Cameselle-Teijeiro J. M., Lopes J. M., Sobrinho-Simões M., Soares P. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 2012;97:E1139–E1149. doi: 10.1210/jc.2011-2748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2011-2748</ArticleId>
            <ArticleId IdType="pubmed">22549934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Souza E. C., Padrón A. S., Braga W. M., de Andrade B. M., Vaisman M., Nasciutti L. E., Ferreira A. C., de Carvalho D. P. MTOR downregulates iodide uptake in thyrocytes. J. Endocrinol. 2010;206:113–120. doi: 10.1677/JOE-09-0436.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1677/JOE-09-0436</ArticleId>
            <ArticleId IdType="pubmed">20392814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antico Arciuch V. G., Russo M. A., Kang K. S., Di Cristofano A. Inhibition of AMPK and Krebs cycle gene expression drives metabolic remodeling of Pten-deficient preneoplastic thyroid cells. Cancer Res. 2013;73:5459–5472. doi: 10.1158/0008-5472.CAN-13-1429.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-13-1429</ArticleId>
            <ArticleId IdType="pmc">PMC3766458</ArticleId>
            <ArticleId IdType="pubmed">23796563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen G., Xu S., Renko K., Derwahl M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J. Clin. Endocrinol. Metab. 2012;97:E510–E520. doi: 10.1210/jc.2011-1754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2011-1754</ArticleId>
            <ArticleId IdType="pubmed">22278418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klubo-Gwiezdzinska J., Jensen K., Costello J., Patel A., Hoperia V., Bauer A., Burman K. D., Wartofsky L., Vasko V. Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells. Endocr. Relat. Cancer. 2012;19:447–456. doi: 10.1530/ERC-12-0046.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1530/ERC-12-0046</ArticleId>
            <ArticleId IdType="pubmed">22389381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klubo-Gwiezdzinska J., Costello J., Jr, Patel A., Bauer A., Jensen K., Mete M., Burman K. D., Wartofsky L., Vasko V. Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J. Clin. Endocrinol. Metab. 2013;98:3269–3279. doi: 10.1210/jc.2012-3799.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2012-3799</ArticleId>
            <ArticleId IdType="pubmed">23709654</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
